BIGBEAR
PHARMACEUTICAL
Adagrasib is a highly selective, orally administered KRAS G12C inhibitor used for the treatment of patients with advanced cancers harboring a KRAS G12C mutation.
AuthenticGuaranteeFast DeliveryPrivacy FDA Approval AnnouncementOn December 12, 2022, Mirati Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted accelerated ···【More】
Update: 10 Mar,2026Source: BigbearViews: 95
FDA Approval AnnouncementOn December 12, 2022, Mirati Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted accelerated appr···【More】
Update: 10 Mar,2026Source: BigbearViews: 92
Lung Cancer Epidemiology in the UKEach year, more than 43,000 people are diagnosed with lung cancer in the UK.Non-small cell lung cancer (NSCLC) is th···【More】
Update: 10 Mar,2026Source: BigbearViews: 94
FDA Approval AnnouncementOn June 21, Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval to KRAZATI (adagrasib) in combi···【More】
Update: 10 Mar,2026Source: BigbearViews: 92
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
